Peptide Library / Detail
LL-37
Half-life
Short; rapidly degraded by proteases (minutes in biological fluids), context-dependent with topical matrices potentially prolonging effect
Delivery
Primarily topical or localized/intradermal application in research; formulations often use gels, creams, or hydrogel dressings to improve stability and retention.
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
LL-37 (Human Cathelicidin) is the C-terminal, active form of the human cathelicidin (hCAP18). It exhibits broad-spectrum antimicrobial activity and immunomodulatory effects, and is studied for roles in wound repair, biofilm disruption, and epithelial barrier defense.
Usage
Used in research on chronic wounds, skin/mucosal defense, biofilm-related infections, and innate immunity signaling.
Mechanism of Action
Disrupts microbial membranes via amphipathic helical insertion; modulates TLR signaling and cytokine/chemokine release; promotes keratinocyte migration/angiogenesis and can neutralize LPS to reduce endotoxin-driven inflammation.
Benefits(4)
- Broad-spectrum antimicrobial and anti-biofilm activity
- Supports wound closure and re-epithelialization
- Enhances local immune surveillance and barrier function
- LPS neutralization and modulation of inflammatory signaling
Side Effects(4)
- Local irritation, burning, or erythema at application site
- Pro-inflammatory effects at higher concentrations
- Potential flare of inflammatory dermatoses (e.g., psoriasis models)
- Rare hypersensitivity reactions